BPH Clinical Trial
Official title:
EFFICACY EVALUATION OF PRUNUS DOMESTICA EXTRACT ON BENIGN PROSTATE HYPERPLASIA (BPH): An Add on Study
Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate Prunus
domestica bark contains three groups of active constituents: phytosterols (including
beta-sitosterol), pentacyclic triterpenoids (including ursolic and oleaic acids) and ferulic
esters of long-chain fatty alcohols (including ferulic esters of docosanol and
tetracosanol).
The phytosterols, particularly beta-sitosterol, are found in numerous plants and are
anti-inflammatory, inhibiting the synthesis of prostaglandins. Beta-sitosterol has been
shown to be useful in cases of BPH by helping to reduce the normally elevated levels of
prostaglandins in these patients.
Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate. Symptoms
related to BPH are one of the most common problems in older men. Histological evidence of
BPH is found in more than is approximately 10% for men in their 30s, 20% for men in their
40s, reaches 50% to 60% for men in their 60s, and is 80% to 90% for men in their 70s and
80s. The majority of men over the age of 60 are considered to have urinary symptoms
attributable to BPH.
The proliferative disorder resulting in BPH affects both the stromal and the epithelial
portions of the prostate. The enlarging prostate results in the progressive occlusion of the
proximal urethra and can result in both obstructive and irritative urinary tract symptoms.
The preferred medical treatment for many men with symptomatic benign prostatic hyperplasia
is either an alpha-adrenergic-receptor antagonist (alpha-blocker), which reduces
smooth-muscle tone in the prostate, and bladder neck, or a 5α-reductase inhibitor, which
reduces prostate volume by inducing epithelial atrophy. These drugs have side effects
including:-dizziness, fatigue, hypotension, headache, insomnia, gynecomastia, and retrograde
ejaculation.
The use of plants and herbs for medicinal purposes (phytotherapy) including treatment of BPH
symptoms has been growing steadily in most countries. Usage of plant extracts is common in
many countries of the world and is increasing in the United States. Phytotherapeutic agents
represent nearly half of the medications dispensed for BPH in Italy, compared with 5% for
alpha blockers and 5% for 5-alpha reductase inhibitors. In Germany and Austria, phytotherapy
is the first-line treatment for mild to moderate urinary obstructive symptoms and represents
> 90% of all drugs prescribed for the treatment of BPH. In the United States their use has
also markedly increased, they are readily available as nonprescription dietary supplements
and are often recommended in "natural health food stores or books" for self treatment of BPH
symptoms.
Prunus domestica, or European plum, is a small deciduous tree in the Rosaceae (rose) family
that is an ancient domesticated species, known only in cultivation. It is now cultivated in
temperate areas worldwide for its fruit.
Mechanism of action The bark contains three groups of active constituents: phytosterols
(including beta-sitosterol), pentacyclic triterpenoids (including ursolic and oleaic acids)
and ferulic esters of long-chain fatty alcohols (including ferulic esters of docosanol and
tetracosanol).
The phytosterols, particularly beta-sitosterol, are found in numerous plants and are
anti-inflammatory, inhibiting the synthesis of prostaglandins. Beta-sitosterol has been
shown to be useful in cases of BPH by helping to reduce the normally elevated levels of
prostaglandins in these patients. The elimination of the excess blood and vasal congestion
helps reduce the size of prostate adenomas. The pentacyclic triterpenoids also help inhibit
inflammation by blocking enzymatic activity. They are effective anti-edema agents and also
help increase the integrity of small veins and capillaries. The third active group, the
ferulic esters of long-chain fatty acids, act by inhibiting the absorption and metabolism of
cholesterol. BPH and other cases of enlarged prostates are characterized by containing
abnormally high levels of cholesterol. Plant efficacy was determined by measuring the
effects of the herb on numerous parameters, including dysuria, nycturia, frequent urination,
abdominal heaviness, residual urine, voiding volume, prostate volume, and peak flow.
Consumption of P.Domestica resulted in significant amelioration of symptoms, reduction in
prostate size, and clearance of bladder neck urethral obstruction.
Different studies suggest that these phytochemicals appear to work synergistically to
improve the symptoms of BPH. However, the most bioactive phytochemicals in pygeum are the
phytosterols. Therefore, these components of pygeum extract are believed to exert the most
important therapeutic effect in the treatment of BPH.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02974751 -
Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
|
||
Terminated |
NCT04398966 -
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT04029012 -
Penthrox in Rezūm BPH
|
Phase 4 | |
Recruiting |
NCT03912558 -
Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients.
|
N/A | |
Completed |
NCT00527488 -
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
|
Phase 2 | |
Recruiting |
NCT06323109 -
US Imaging for the Assessment of LUTS
|
||
Completed |
NCT05628025 -
Simulation-Based Enucleation Training: Initial Experience Using 3D-printed Organ Phantoms
|
||
Completed |
NCT00407329 -
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00256399 -
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
|
N/A | |
Terminated |
NCT03994263 -
A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI
|
N/A | |
Completed |
NCT03772808 -
Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS)
|
N/A | |
Completed |
NCT05818670 -
Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study
|
Phase 4 | |
Withdrawn |
NCT02961114 -
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04198103 -
Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia
|
N/A | |
Completed |
NCT00696761 -
The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
|
Phase 4 | |
Completed |
NCT00199550 -
Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP)
|
Phase 4 | |
Completed |
NCT00154843 -
A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation
|
Phase 2 | |
Completed |
NCT00037141 -
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05620784 -
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
|
Phase 3 | |
Not yet recruiting |
NCT05719220 -
Effect of Group Preoperative Pelvic Floor Training for HoLEP
|